{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:12:49Z","timestamp":1761718369951,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.nucmedbio.2015.01.008","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T00:19:57Z","timestamp":1422663597000},"page":"598-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-\u03b2, and\/or bevacizumab for glioblastoma"],"prefix":"10.1016","volume":"42","author":[{"given":"Takahiro","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-8091","authenticated-orcid":false,"given":"Toshio","family":"Sasajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kanagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsumi","family":"Baden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Mizoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.coc.0000045852.88461.80","article-title":"Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma","volume":"27","author":"Gruber","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0015","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0020","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1158\/0008-5472.CAN-05-0036","article-title":"IFN-\u03b2 down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide","volume":"65","author":"Natsume","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-007-0520-x","article-title":"A combination of IFN-\u03b2 and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation","volume":"61","author":"Natsume","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0030","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.25637","article-title":"Benefits of interferon-\u03b2 and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study","volume":"117","author":"Motomura","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0045","first-page":"1399","article-title":"Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A","volume":"9","author":"Lamszus","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0050","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1593\/neo.08928","article-title":"Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model","volume":"10","author":"Mathieu","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/noq206","article-title":"Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab","volume":"13","author":"Ellingson","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11910-011-0179-x","article-title":"Advances in MRI assessment of gliomas and response to anti-VEGF therapy","volume":"11","author":"Pope","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0065","doi-asserted-by":"crossref","first-page":"690585","DOI":"10.1155\/2013\/690585","article-title":"Early pseudoprogression following chemoradiotherapy in glioblastoma patients: The value of RANO evaluation","volume":"2013","author":"Linhares","year":"2013","journal-title":"J Oncol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0070","doi-asserted-by":"crossref","first-page":"E622","DOI":"10.1152\/ajpendo.00187.2004","article-title":"Na+-dependent neutral amino acid transporters A, ASC, and N of the blood-brain barrier: mechanisms for neutral amino acid removal","volume":"287","author":"O'Kane","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11307-007-0115-2","article-title":"11C-l-methionine positron emission tomography in the clinical management of cerebral gliomas","volume":"10","author":"Singhal","year":"2008","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0080","first-page":"56","article-title":"Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET\/CT in prostate carcinoma","volume":"48","author":"Schuster","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0085","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2967\/jnumed.110.086074","article-title":"Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer","volume":"52","author":"Okudaira","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0090","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.nucmedbio.2013.04.007","article-title":"Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-l-methionine and magnetic resonance imaging for monitoring treatment response in gliomas","volume":"40","author":"Sasajima","year":"2013","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0095","first-page":"331","article-title":"Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors","volume":"40","author":"Shoup","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nucmedbio.2011.06.008","article-title":"Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells","volume":"39","author":"Oka","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0105","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s00259-004-1512-2","article-title":"Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines","volume":"31","author":"Sasajima","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/jcbfm.1986.8","article-title":"Triple-tracer autoradiography of cerebral blood flow, glucose utilization, and protein synthesis in rat brain","volume":"6","author":"Mies","year":"1986","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1005781210974","article-title":"Intracarotid recombinant human tumor necrosis factor-alpha reduces cerebral blood flow and methionine uptake in rat brain tumors","volume":"34","author":"Sasajima","year":"1997","journal-title":"J Neurooncol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/neuonc\/nos260","article-title":"Detection of glioblastoma response to temozolomide combined with bevacizumab based on \u03bcMRI and \u03bcPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy","volume":"15","author":"Corroyer-Dulmont","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0125","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0140","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/1078-0432.CCR-10-1868","article-title":"Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells","volume":"17","author":"von Baumgarten","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0145","first-page":"1250","article-title":"Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl-L-methionine","volume":"41","author":"Langen","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0150","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00259-001-0690-4","article-title":"Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET","volume":"29","author":"Chung","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s101430050018","article-title":"Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining","volume":"22","author":"Sato","year":"1999","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2007-991143","article-title":"Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation","volume":"50","author":"Roessler","year":"2007","journal-title":"Minim Invasive Neurosurg"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00259-009-1219-5","article-title":"Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme","volume":"37","author":"Galldiks","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2310\/7290.2011.00014","article-title":"Imaging of non- or very subtle contrast-enhancing malignant gliomas with [11C]-methionine positron emission tomography","volume":"10","author":"Galldiks","year":"2011","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0175","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2967\/jnumed.110.086645","article-title":"O-(2-18F-fluoroethyl)-l-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma","volume":"52","author":"Hutterer","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0180","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00259-012-2251-4","article-title":"Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI","volume":"40","author":"Galldiks","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2967\/jnumed.111.092387","article-title":"3\u2032-deoxy-3\u2032-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab","volume":"53","author":"Schwarzenberg","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0190","doi-asserted-by":"crossref","first-page":"205818","DOI":"10.1155\/2012\/205818","article-title":"Usefulness of FDG, MET and FLT-PET studies for the management of human gliomas","volume":"2012","author":"Miyake","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0195","first-page":"1612","article-title":"Kinetic analysis of 3\u2032-deoxy-3\u2032-18F-fluorothymidine in patients with gliomas","volume":"47","author":"Muzi","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2015.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.50.5.1316","article-title":"11C-methionine PET for differential diagnosis of low-grade gliomas","volume":"50","author":"Herholz","year":"1998","journal-title":"Neurology"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805115000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805115000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T07:21:22Z","timestamp":1566285682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805115000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0969805115000207"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.01.008","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-\u03b2, and\/or bevacizumab for glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2015.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}